Moderna (MRNA) Gross Profit (2020 - 2026)

Moderna has reported Gross Profit for 7 years, with the latest figure at $52.0 million in Q2 2026.

• Gross Profit for Q2 2026 came in at $52.0 million, up 126.09% year-over-year; the trailing twelve-month figure through Jun 2026 was $521.0 million (down 67.76% YoY), and the FY2025 annual result was $1.1 billion, down 39.28% from the prior year.
• Gross Profit grew to $52.0 million in Q2 2026, from -$566.0 million in the prior quarter.
• Over five years, Gross Profit peaked at $5.0 billion in Q1 2022 and troughed at -$566.0 million in Q1 2026.
• A 5-year average of $1.1 billion and a median of $226.5 million in 2024 frame the typical range for Gross Profit.
• The widest annual swing landed in 2024, when Gross Profit soared 428.78%; it then plunged 3244.44% in 2026.
• A 5-year view of Gross Profit shows it stood at $4.7 billion in 2022, then plunged by 59.82% to $1.9 billion in 2023, then plunged by 87.94% to $227.0 million in 2024, then dropped by 0.44% to $226.0 million in 2025, then plunged by 76.99% to $52.0 million in 2026.
• Per Business Quant data, the three most recent Gross Profit figures were $52.0 million in Q2 2026, -$566.0 million in Q1 2026, and $226.0 million in Q4 2025.